Upregulated microRNA‐193a‐3p is responsible for cisplatin resistance in CD44(+) gastric cancer cells

Cisplatin is a well‐known anticancer drug used to treat various cancers. However, development of cisplatin resistance has hindered the efficiency of this drug in cancer treatment. Development of chemoresistance is known to involve many signaling pathways. Recent attention has focused on microRNAs (m...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, So D., Yu, Dayeon, Lee, Do Y., Shin, Hyun‐Soo, Jo, Jeong‐Hyeon, Lee, Yong C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361556/
https://www.ncbi.nlm.nih.gov/pubmed/30485589
http://dx.doi.org/10.1111/cas.13894

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361556/
https://www.ncbi.nlm.nih.gov/pubmed/30485589
http://dx.doi.org/10.1111/cas.13894

Ejemplares similares